Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
17 janv. 2024 07h15 HE
|
CytoSorbents
CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial
Patient with Second Historic Pig Heart Transplant Treated with Novel Investigational Antibody Therapy Produced at Berkshire Sterile Manufacturing
27 sept. 2023 13h00 HE
|
Berkshire Sterile Manufacturing
Lee, MA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- A historic transplant of a genetically modified pig heart has been successfully performed on a 20-year Navy veteran and married father of two suffering...
$4.5+ Billion Artificial Heart Market Size to Exhibit CAGR of 15+% by 2028, Deep Dive Analysis of Key Players and Growth Opportunities
12 oct. 2022 09h16 HE
|
The Insight Partners
New York, Oct. 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners recently published a report on "Artificial Heart Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact...
BIOLIFE4D Announces Intention to Submit Draft Registration Statement for Underwritten Public Offering of Common Stock
31 déc. 2021 09h15 HE
|
BIOLIFE4D
BUFFALO GROVE, Ill., Dec. 31, 2021 (GLOBE NEWSWIRE) -- BIOLIFE4D Corporation today announced that it intends to submit a draft registration statement on Form S-1 with the U.S. Securities and...
Cardiac surgery instruments Market To Reach USD 2.06 Billion By 2027 | Reports And Data
28 janv. 2020 10h00 HE
|
Reports and Data
New York, Jan. 28, 2020 (GLOBE NEWSWIRE) -- The Global Cardiac Surgery Instruments Market is forecast to reach USD 2.06 Billion by 2027, according to a new report by Reports and Data. Cardiac...
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Following Significant Scientific Achievement
16 sept. 2019 08h00 HE
|
BIOLIFE4D
Company surpasses $3M in accepted investments CHICAGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for...
BIOLIFE4D Launches Second Regulation A+ (Mini-IPO) Offering Due to Popular Demand
06 sept. 2019 07h30 HE
|
BIOLIFE4D
CHICAGO, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has launched its...
BIOLIFE4D Appoints Management Advisory Board
28 janv. 2019 08h30 HE
|
BIOLIFE4D Corporation
CHICAGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has established a...
BIOLIFE4D Successfully Demonstrates Ability to 3D Bioprint Human Cardiac Tissue
25 juin 2018 08h00 HE
|
BIOLIFE4D Corporation
CHICAGO, June 25, 2018 (GLOBE NEWSWIRE) -- BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully...
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
23 juin 2018 08h00 HE
|
BIOLIFE4D Corporation
CHICAGO, June 23, 2018 (GLOBE NEWSWIRE) -- BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it will be modifying...